Cleared Traditional

K241313 - OHC COVID-19 Antigen Self Test (FDA 510(k) Clearance)

Class II Microbiology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K241313 · Osang, LLC · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 2025
Decision
386d
Days
Class 2
Risk

K241313 is an FDA 510(k) clearance for the OHC COVID-19 Antigen Self Test. Classified as Over-the-counter Covid-19 Antigen Test (product code QYT), Class II - Special Controls.

Submitted by Osang, LLC (Pasadena, US). The FDA issued a Cleared decision on May 30, 2025 after a review of 386 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3984 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Osang, LLC devices

Submission Details

510(k) Number K241313 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 09, 2024
Decision Date May 30, 2025
Days to Decision 386 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
284d slower than avg
Panel avg: 102d · This submission: 386d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code QYT Over-the-counter Covid-19 Antigen Test
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3984
Definition For The Rapid, Qualitative Detection Of Sars-cov-2 Virus Nucleocapsid Protein Antigen In Individuals 2 Years And Older.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Consultant

Hyman, Phelps & McNamara, P.C.
Lisa Baumhardt

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - QYT Over-the-counter Covid-19 Antigen Test

All 12
Devices cleared under the same product code (QYT) and FDA review panel - the closest regulatory comparables to K241313.
Heal-Check Rapid COVID-19 Antigen Self-Test
K260095 · Healgen Scientific, LLC · Apr 2026
GenBody COVID-19 Ag Home Test
K251916 · Genbody.Inc. · Mar 2026
COVID-19 Detect Rapid Self -Test
K251595 · InBios International, Inc. · Oct 2025
GenaCheck COVID-19 Rapid Self-Test
K251753 · Genabio Diagnostics, Inc. · Sep 2025
BinaxNOW™ COVID-19 Antigen Self Test
K243518 · Abbott Diagnostics Scarborough, Inc. · Feb 2025
CareSuperb™ COVID-19 Antigen Home Test
K241915 · Access Bio, Inc. · Jan 2025